Vad Szilvia, Lakos Gabriella, Kiss Emese, Sipka Sàndor, Csorba Roland, Poka Robert
Department of Obstetrics and Gynaecology, University of Debrecen Health Science Centre, Debrecen, Hungary.
Blood Coagul Fibrinolysis. 2003 Jan;14(1):57-60. doi: 10.1097/00001721-200301000-00010.
The role of thrombophilia in the elevated risk of thromboembolism during oral contraceptive use has been established. We performed a cross-sectional study among young women to survey the occurrence of antiphospholipid antibodies among users and non-users of oral contraceptives. Serum levels of immunoglobulin (Ig)G, IgA and IgM isotypes of anti-beta2-glycoprotein I and anticardiolipin antibodies were measured by validated enzyme-linked immunosorbent assay methods. Combining all types of antiphospholipid antibodies, pill-users had an elevated antibody titre more than twice as frequently as non-users (odds ratio, 2.3; 95% confidence interval, 1.1-5.1). The higher frequency of elevated antibody titre was related most commonly to IgG type anti-beta2-glycoprotein I antibodies. Oral contraceptive use increases the risk of elevated antiphospholipid antibody levels among asymptomatic young women.
血栓形成倾向在口服避孕药期间血栓栓塞风险升高方面的作用已得到证实。我们在年轻女性中进行了一项横断面研究，以调查口服避孕药使用者和非使用者中抗磷脂抗体的发生情况。通过经过验证的酶联免疫吸附测定方法测量抗β2-糖蛋白I和抗心磷脂抗体的免疫球蛋白（Ig）G、IgA和IgM同种型的血清水平。综合所有类型的抗磷脂抗体，避孕药使用者抗体滴度升高的频率是非使用者的两倍多（比值比，2.3；95%置信区间，1.1-5.1）。抗体滴度升高的较高频率最常与IgG型抗β2-糖蛋白I抗体有关。口服避孕药会增加无症状年轻女性抗磷脂抗体水平升高的风险。
